Risk Factors Update Summary

• Accumulated deficit increased from $737 million to $824 million as of December 31, 2023.
• Obtained FDA fast track designation for combination of avutometinib and LUMAKRAS for KRAS G12C - mutant metastatic NSCLC.
• Cash resources may not be sufficient to fund operations through the next 12 months.
• Increase in Consumer Price Index from 3.4% to 4% may impact financial results.
• Risks associated with patent protection, including challenges to validity and enforcement, could impact business operations.
• Seeking fast track designation for additional product candidates, but may not receive it.
• Need for additional funding due to insufficient cash to meet future financial obligations.
• Potential loss of exclusivity due to challenges in protecting intellectual property rights.
• Increased cybersecurity risks due to evolving cyberattacks, requiring significant resources for protection.
• Potential limitations on using net operating loss carryforwards due to changes in stock ownership.
• Capital stock price fluctuated from a high of $194 to a low of $3 in 2023.
• Series B Convertible Preferred Stock outstanding shares convertible into 4,236,570 shares of common stock.
• Potential substantial dilution to existing stockholders if outstanding shares of Series B Convertible Preferred Stock are converted.
• Ongoing healthcare reform efforts may impact drug pricing and payment, affecting commercialization.